Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2004-03-25 Annual Report
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Annual Report 2003
Annual Report
2004-03-25 English
Quarterly Report 3/2003
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Evotec OAI AG, Third Quarter Report 2003' and contains detailed financial data for the first nine months and the third quarter of 2003, including revenue growth, EBITDA, segment performance, and cost structure. It discusses operational highlights, new collaborations, and financial results with specific figures and analysis. The length is substantial (15,000 characters), and the content includes comprehensive financial statements and business commentary for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR).
2003-11-12 German
Evotec OAI AG english
Regulatory Filings Classification · 100% confidence The document is a 'News Details' announcement from 'Evotec OAI AG' dated October 22, 2003, sent via DGAP. The content describes a business development: the expansion of a partnership with Roche for medicinal chemistry collaboration in oncology. This is a corporate announcement regarding a strategic business agreement, not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). It does not fit the specific definitions for AGM-R, AR, MANG, CT, CAP, DVA, DLST, DIRS, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, NAV, PSI, DEF 14A, RPA, SHA, or POS. Since it is a general corporate news announcement that doesn't fit the highly specific categories, the most appropriate fallback is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings.
2003-10-22 English
Evotec OAI AG english
M&A Activity Classification · 99% confidence The document is a 'News Details' announcement dated October 14, 2003, detailing a co-marketing and distribution agreement between Evotec OAI AG and Biofrontera Pharmaceuticals Holding AG regarding drug discovery services. This is a corporate action announcement concerning a business partnership, not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general corporate news announcement that doesn't fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Capital Change (CAP), the most appropriate fallback category is Regulatory Filings (RNS), which serves as the general category for miscellaneous corporate announcements distributed via news services (like DGAP mentioned in the text). The document length is relatively short (4855 chars), but it is the substance of the announcement itself, not an announcement *about* another report.
2003-10-14 English
Evotec OAI AG english
Regulatory Filings Classification · 100% confidence The document is a 'Corporate-news announcement sent by DGAP' dated September 19, 2003. It details a partnership between three entities (Max Planck Institute, Evotec Technologies, and Definiens) regarding RNAi screening technology. This type of announcement, which communicates business developments, partnerships, or general corporate news via a regulatory news service (DGAP), does not fit the specific definitions for financial reports (10-K, IR, ER), shareholder actions (DIV, DVA), or management changes (MANG). Since it is a general corporate news announcement distributed through a regulatory channel and doesn't fit any other specific category, the most appropriate fallback is 'Regulatory Filings' (RNS). The document length is substantial (8824 chars), so it is not a simple RPA.
2003-09-19 English
Evotec OAI AG english
Regulatory Filings Classification · 95% confidence The document is a 'Corporate-news announcement' dated September 10, 2003, detailing a 'Strategic Drug Discovery and Development Alliance' between Evotec OAI and DeveloGen. It describes a partnership, risk-sharing, and future plans, which is a significant business event announcement. This type of announcement, which is not a formal regulatory filing like a 10-K, nor a specific financial report (ER, IR), nor a management change (MANG), nor a director dealing (DIRS), fits best under the general category for corporate news that doesn't fit elsewhere, which is Regulatory Filings (RNS), as it is a general corporate disclosure sent via a news service (DGAP). It is too detailed to be a simple Report Publication Announcement (RPA) and is not about financing (CAP), dividends (DIV), or voting (DVA).
2003-09-10 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.